Cite
Lohinai Z, Klikovits T, Moldvay J, et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep. 2017;7:39721doi: 10.1038/srep39721.
Lohinai, Z., Klikovits, T., Moldvay, J., Ostoros, G., Raso, E., Timar, J., Fabian, K., Kovalszky, I., Kenessey, I., Aigner, C., Renyi-Vamos, F., Klepetko, W., Dome, B., & Hegedus, B. (2017). KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Scientific reports, 739721. https://doi.org/10.1038/srep39721
Lohinai, Zoltan, et al. "KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis." Scientific reports vol. 7 (2017): 39721. doi: https://doi.org/10.1038/srep39721
Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, Renyi-Vamos F, Klepetko W, Dome B, Hegedus B. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep. 2017 Jan 04;7:39721. doi: 10.1038/srep39721. PMID: 28051122; PMCID: PMC5209707.
Copy
Download .nbib